---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127004"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:29:53.152285+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC

## Summary
- Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.
- Cash $32.4M, expected to fund operations into Q4 2025; $12M public offering priced in quarter.
- CUE-101 + KEYTRUDA Phase 1 data: 46% ORR, 91.3% 12-month OS, 21.8-month mOS in 1L HPV+ HNSCC.
- CUE-102 monotherapy: 67% DCR in late-stage pancreatic cancer; favorable tolerability with no DLTs.
- Appointed Lucinda Warren as Chief Business Officer; preclinical autoimmune programs advancing.

## SEC filing metadata
- accession: 0000950170-24-127004
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/0000950170-24-127004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/cue-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127004
- JSON: https://secwatch.observer/filing/0000950170-24-127004.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.